J&J resumes roll-out of COVID-19 vaccine in EU
21st April 2021 Uncategorised 0EMA’s safety committee has confirmed the overall benefit-risk profile of the jab More: J&J resumes roll-out of COVID-19 vaccine in EU Source: News
read more
EMA’s safety committee has confirmed the overall benefit-risk profile of the jab More: J&J resumes roll-out of COVID-19 vaccine in EU Source: News
read moreFirst self-administered, targeted B-cell therapy licensed for adults with relapsing forms of MS More: Novartis’ MS therapy Kesimpta wins NICE backing Source: News
read moreAntivirals Taskforce established in a bid to identify promising at-home antiviral medicines More: UK government launches search for at-home COVID-19 treatments Source: News
read moreJ&J won’t pursue Erleada, Zytiga prostate cancer combo after trial results disappoint nhigginsdunn Tue, 04/20/2021 – 11:47 More: J&J won't pursue Erleada, Zytiga prostate cancer combo after trial results disappoint Source: fierce
read moreJohnson & Johnson sees ‘very viable path forward’ for its COVID-19 vaccine despite safety, manufacturing setbacks esagonowsky Tue, 04/20/2021 – 11:01 More: Johnson & Johnson sees 'very viable path forward' for its COVID-19 vaccine despite safety, manufacturing setbacks Source: fierce
read moreAstellas innovation awards offer up ideas to ease cancer patients’ pandemic burdens bbulik Tue, 04/20/2021 – 10:40 More: Astellas innovation awards offer up ideas to ease cancer patients' pandemic burdens Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals